Torii Pharmaceutical Co.
Torii Nihonbashi Bldg.
10 articles with Torii Pharmaceutical Co.
Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102 in Japan
Verrica Pharmaceuticals Inc. announced it has entered into an Option Agreement with Torii Pharmaceutical Co., Ltd. granting Torii an exclusive option to acquire an exclusive license to develop and commercialize Verrica’s product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102.
Dermavant Enters into Exclusive License Agreement with JT for Development and Commercialization of Tapinarof in Japan
JT and its subsidiary, Torii Pharmaceutical, receive rights to develop and commercialize tapinarof for psoriasis and atopic dermatitis in Japan
BioCryst Announces Partnership With Torii Pharmaceutical to Commercialize BCX7353 in Japan for the Prevention of HAE Attacks
BioCryst Pharmaceuticals, Inc. announced that it has licensed commercialization rights in Japan to Torii Pharmaceutical, Co. for BCX7353, an oral, once-daily treatment for the prevention of hereditary angioedema attacks..
Akebia Therapeutics Announces Collaboration Partner’s Positive Top-line Results of Phase 3 Clinical Study of Riona® (ferric citrate hydrate) in Adult Patients with Iron Deficiency Anemia in Japan
Upon successful completion of its Phase 3 program, JT and Torii stated that they expect to file an application for approval of IDA as an additional indication for Riona in Japan.
ALK-Abello A/S’s Partner, Torii Pharmaceutical Co., Gains Approval For Japanese Cedar SLIT-Tablet In Japan
Keryx Biopharmaceuticals Announces Positive Top-Line Results from Phase 3 Study of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco, Inc. and Torii Pharmaceutical Co.
Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex(TM)) in Japan by Partner, Japan Tobacco, Inc. and Torii Pharmaceutical Co.
Keryx Biopharmaceuticals Licenses Rights to Japan Tobacco; Torii Pharmaceutical Co. to Pay up to $100 Million
Torii Pharmaceutical Co., Toray Industries, Inc. Start to Co-Promote Hemoperfusion Absorption Column Toraymyxin for Removing Endotoxin
Nippon Chemiphar Co., Ltd. And Torii Pharmaceutical Co. To Terminate Sales Tie-Up For Urinary Alkalizer